nep

Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal

Candoxatril (UK 79300) is a small-molecule inhibitor and a neutral endopeptidase (NEP) inhibitor with oral activity and cell permeability, used for the treatment of chronic heart failure and capable of improving exercise capacity in patients receiving angiotensin-converting enzyme inhibitor therapy.

Racecadotril (Acetorphan) has been investigated for the basic science and treatment of Diarrhea, Acute Diarrhea, and Acute Gastroenteritis.

Sacubitril hemicalcium salt (AHU377 calcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696. Sacubitril hemicalcium salt is a prodrug of LBQ657, which is an inhibitor of the zinc metallopeptidase neprilysin. Neprilysin degrades a variety of vasoactive peptides such as atrial and brain natriuretic peptide, bradykinin, adrenomedullin, and endothelin-1. Inhibition of neprilysin leads to an increased level of these peptides and, thus, antihypertensive effects. Formulations containing AHU377 in combination with the angiotensin II receptor antagonist valsartan are used to treat hypertension and heart failure.

Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM and is a component of the heart failure medicine LCZ696.

SCH 42495 is an orally active neutral metalloendopeptidase inhibitor and serves as the ethyl ester prodrug of SCH 42354.

SCH 42495 racemate is the racemate of SCH 42495, an orally active neutral inhibitor of metalloendopeptidase (NEP) with antihypertensive effects.

SQ28603 is a potent and selective inhibitor of neutral endopeptidase 3.4.24.11 (NEP).

TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.

Omapatrilat is an orally active dual inhibitor of ACE (angiotensin-converting enzyme) and NEP (neprilysin), with Ki values of 0.64 and 0.45 nM, respectively, capable of suppressing induced hypotension in rats.

Phosphoramidon Disodium (Phosphoramidon Disodium Salt) Salt is a metalloendopeptidase inhibitor, widely used as a biochemical tool.

Thiorphan is an neprilysin inhibitor (NEP; IC50 : 0.007 μM).

Sacubitrilat (LBQ-657) (LBQ657) is an effective inhibitor of active neprilysin (NEP).

NEP-IN-1 is an inhibitor of neutral endopeptidase (NEP, IC50 = 2 nM) and can be used in studies about female sexual arousal disorders.

NEP-IN-2 is a neutral endopeptidase inhibitor used in the research of proliferation in atherosclerosis and restenosis.

NEP(1-40), N-terminal uncapped, is an analog of NEP(1-40) without acetylation at the N-terminus. NEP(1-40) acts as a peptide antagonist of the Nogo-66 receptor (NgR).

NEP-28 is an AR agonist. NEP28 is a new SARM exhibiting high selectivity for androgen receptor. NEP28 showed tissue-selective effect equivalent to or higher than existing SARMs. In addition, the administration of NEP28 increased the activity of neprilysin, a known Aβ-degrading enzyme.

NEP(1-40) TFA is a peptide antagonist of the Nogo-66 receptor (NgR), which attenuates myelin-derived inhibition and mitigates injury-induced shifts in microglial morphology distributions [1].

NEP162 is a BRD4 PROTAC degrader with DC50 values of 1.2 μM in SW480 cells and 1.6 μM in U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibiting tumor growth and inducing apoptosis. It is applicable in research on cancers such as osteosarcoma, colorectal cancer, and non-small cell lung cancer.

NEP108 is a BRD4 PROTAC degrader designed based on GID4 E3 ligase, with a DC50 of approximately 3.8 μM. It exhibits strong affinity for GID4, with a KD value of 0.22 μM, and a ternary complex KD value of 2.85 μM. NEP108 can be utilized for cancer research.

NEP202 is a SMARCA2 PROTAC degrader designed based on the GID4 E3 ligase. NEP168 is suitable for cancer research.

NEP168 is an ERα PROTAC degrader designed based on the GID4 E3 ligase. It is intended for breast cancer research.

TAT-NEP1-40, a blood-brain barrier (BBB) permeable peptide, confers protection to PC12 cells against oxygen and glucose deprivation (OGD) while promoting neurite outgrowth. Furthermore, it enhances neurologic outcomes post-ischemia by mitigating apoptosis in affected cerebral regions. This compound holds potential for central nervous system (CNS) injury research, including studies on axonal regeneration and post-stroke functional recovery [1].